- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Dexpramipexole, Dexpramipexole Placebo, Moxifloxacin
- Drug
- Lead sponsor
- Knopp Biosciences
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 265–288
of 314
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Acne Vulgaris
- Interventions
- SB204 4%, SB204 8% or 12%, Vehicle
- Drug
- Lead sponsor
- Novan, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- West Bend, Wisconsin
- Conditions
- Dyslipidemia
- Interventions
- K-877 Low Dose, Moxifloxacin, Placebo, K-877 High Dose
- Drug · Other
- Lead sponsor
- Kowa Research Institute, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2014
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Tuberculosis
- Interventions
- SQ109, SQ109 Placebo, Moxifloxacin
- Drug · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Ends 2015
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Healthy Volunteers
- Interventions
- Ziresovir 125 mg, Ziresovir 500 mg, Placebo, Moxifloxacin hydrochloride tablet 400 mg
- Drug
- Lead sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Healthy Participants
- Interventions
- Povorcitinib, Placebo, Moxifloxacin
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 128 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Healthy
- Interventions
- CR845 0.5 mcg/kg IV, CR845 3 mcg/kg IV, Moxifloxacin 400 mg Oral Tablet, Placebo
- Drug · Other
- Lead sponsor
- Cara Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Pigment Skin
- Interventions
- Sciton Joule System
- Device
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 20 Years to 75 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- HIV Infections
- Interventions
- atazanavir/cobicistat, darunavir/ritonavir dosage #1, darunavir/ritonavir dosage #2, darunavir/ritonavir dosage #3, elvitegravir/cobicistat, dolutegravir, tenofovir alafenamide fumarate (TAF), TAF w/cobicistat, TAF w/cobicistat or ritonavir, efavirenz, darunavir/cobicistat, lopinavir/ritonavir dosage #1, atazanavir/ritonavir/tenofovir dosage #1, rifampicin, ethambutol, isoniazid, pyrazinamide, kanamycin, amikacin, capreomycin, moxifloxacin, levoflaxacin, ofloxacin, ethionamide/prothionamide, terizidone/cycloserine, para-aminosalicylic acid (PAS), high dose INH, bedaquiline, clofazamine, delamanid, linezolid, pretomanid, ethinyl estradiol, etonogestrel implant, nevirapine, amprenavir, abacavir, lopinavir/ritonavir dosage #2, indinavir/ritonavir dosage #1, fosamprenavir/ritonavir, lopinavir/ritonavir dosage #3, atazanavir/ritonavir dosage #1, didanosine delayed release (Videx® EC), emtricitabine, tenofovir, nelfinavir dosage #1, tipranavir/ritonavir, lopinavir/ritonavir dosage #4, raltegravir, etravirine, maraviroc, atazanavir/ritonavir dosage #2, tenofovir/atazanavir/ritonavir dosage #2, nelfinavir dosage #2, indinavir/ritonavir dosage #2, rilpivirine, darunavir/ritonavir dosage #4
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Enrollment
- 1,578 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2020
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • La Jolla, California • Long Beach, California + 26 more
- Conditions
- Sinusitis
- Interventions
- Moxifloxacin (Avelox, BAY12-8039), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 374 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 51
- States / cities
- Birmingham, Alabama • Northport, Alabama • Jonesboro, Arkansas + 45 more
- Conditions
- Drug-Induced Liver Injury
- Interventions
- Moxifloxacin (Avelox, BAY12-8039), Amoxicillin, Amoxicillin plus clavulanic acid, Cefuroxime, Clarithromycin, Doxycycline, Levofloxacin, Telithromycin
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,299,056 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2009
- U.S. locations
- 1
- States / cities
- Many Locations, Delaware
- Conditions
- Skin Pigment
- Interventions
- MOXI
- Device
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 20 Years to 60 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Maxillary Sinusitis
- Interventions
- Telithromycin
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 351 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Healthy Volunteers
- Interventions
- TAK-279, TAK-279 Placebo, Moxifloxacin, Moxifloxacin Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Keratoconus, Ectasia, Degeneration
- Interventions
- Ciprofloxicin or Vigamox or other., Nonsteroidal (Acular, Acuvail, Voltaren Xibrom, etc), Steroid (FML, Pred Forte, Flarex, etc.)
- Drug
- Lead sponsor
- Cxlusa
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 3,493 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 16
- States / cities
- Scottsdale, Arizona • Laguna Hills, California • San Diego, California + 13 more
- Conditions
- Healthy Volunteers
- Interventions
- CTP-543, Moxifloxacin, Placebo
- Drug
- Lead sponsor
- Concert Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Rhegmatogenous Retinal Detachment
- Interventions
- Pars plana vitrectomy, Triamcinolone Acetonide 40mg/mL, Moxifloxacin 0.5% or Polymyxin/Trimethoprim if patient is allergic to moxifloxacin, Prednisolone 1%, Atropine 1%
- Procedure · Drug
- Lead sponsor
- Massachusetts Eye and Ear Infirmary
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 168 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Healthy Participants
- Interventions
- LY3009104, Placebo, moxifloxacin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Daytona Beach, Florida
- Conditions
- Healthy
- Interventions
- PH-797804, Moxifloxacin, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Tuberculosis
- Interventions
- Gatifloxacin, Isoniazid, Levofloxacin, Linezolid, Moxifloxacin
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Healthy Subjects
- Interventions
- Technosphere Inhalation Powder (FDKP), Moxifloxacin, Placebo
- Drug
- Lead sponsor
- Mannkind Corporation
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Tacoma, Washington
- Conditions
- Symptomatic Neurogenic Orthostatic Hypertension, nOH
- Interventions
- Ampreloxetine <Dose A>, Ampreloxetine <Dose B>, Ampreloxetine Placebo, Moxifloxacin, Moxifloxacin Placebo
- Drug
- Lead sponsor
- Theravance Biopharma
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Hypertension
- Interventions
- Nebivolol, Atenolol, Moxifloxacin
- Drug
- Lead sponsor
- Mylan Bertek Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 260 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Healthy Volunteers
- Interventions
- Oral Contraceptive (Ortho Tri-Cyclen or its generic equivalent), CC-99677
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years to 48 Years · Female only
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 3
- States / cities
- Miami, Florida • Marlton, New Jersey • Austin, Texas